|
|
PART D COMPLIANCE REPORT
The new Medicare drug benefit carries both risk and opportunity. Part D Compliance Report is designed to help pharma companies, PBMs, health plans, and others meet these challenges. Qui tam attorneys and federal prosecutors say the new Part D benefit will lead to "a new era of fraud detection and fraud enforcement." Drug pricing experts predict major formulary fights. Meanwhile, HHS Office of Inspector General Chief Counsel Lew Morris says compliance is the key to successfully navigating the Part D benefit. This 12-page monthly newsletter offers detailed advice on the most pressing operational and compliance challenges facing the industry, such as arrangements with PDPs, formulary issues, the role of P&T committees, and the grievance and appeals process.
CHARTER RATES EXPIRE DECEMBER 30, 2005:
For a limited time, Part D Compliance Report is available at the low charter rate of $348 (12 issues/year). Click here to subscribe.
For a limited time, Part D Compliance Report is available at an extra discounted rate when ordered with Rx Compliance Report. Click here.
|
THE LATEST ISSUE OF PART D COMPLIANCE REPORT INCLUDES THESE STORIES:
- Former CMS Administrator Tom Scully explains the new risk areas associated with the Part D benefit including patient avoidance, patient dumping, buying arrangements, tracking payments, and success fees
- HHS OIG Inspector Daniel Levinson outlines the OIG's Special Advisory on Patient Assistance Programs and explains how the OIG evaluates drug reimbursement
- Medicare expert Dan Kracov explains how the MMA is ushering in important changes in evidence-based medicine, systemic controls on products, and the use of new data
- USP briefs media on the next phase of revising the Model Guidelines and the impact on pharma companies
Also included are these stories:
- District of Columbia passes new law allowing the District to sue drug companies for "excessive costs"
- Mary Ellen Allen of Foley & Lardner reviews the defeat of California's prescription drug initiatives
|
EDITORIAL ADVISORY BOARD:
- David Balto, Partner, Robins Kaplan Miller & Ciresi, Washington DC, Former Director, Bureau of Competition, Federal Trade Commission
- Robert Esernio, Ernst & Young, Partner, Ernst & Young, Stamford, CT
- Marie Infante, Partner, Mintz, Levin, Ferris, Glovsky & Popeo, Washington DC
- Patrick Morrissey, Partner, Sidley Austin Brown & Wood, Washington, DC, Former Deputy Staff Director and Chief Health Counsel for the House Energy and Commerce Committee
- Kurt Proctor, Senior V.P., Pharmacy Operations, National Association of Chain Drug Stores, Alexandria, VA
- T. Reed Stephens, Partner, Sonnenschein, Nath & Rosenthal, Washington, DC, Former Trial Attorney, U.S. Department of Justice
|
HOW TO ORDER:
To order, please choose one of the following options:
- One-year subscription -- Charter rate: $348/regular price $398 (12 issues) -- click here
- Multi-issue discounts and licensing agreements -- click here
Note: Part D Compliance Report is delivered in PDF-version only
|
|
|
